Top Gene Interactions
- Metabolism: Hepatic and renal Route of Elimination: Little, if any, is excreted unchanged in the urine; most appears as the degradation products of metabolic transformation in the liver, which are almost completely excreted within 24 hours. Half Life: 1-4 hours
- Uses/Sources: For the treatment of symptoms associated with Vertigo/Meniere's disease, nausea and vomiting, motion sickness and insect bite.
- Health Effects: They cause slurred speech, disorientation and "drunken" behavior. They are physically and psychologically addictive.
- Symptoms: Considerable overdosage can lead to myocardial infarction (heart attack), serious ventricular dysrhythmias, coma and death.
- Treatment: There is no specific antidote for diphenhydramine toxicity, but the anticholinergic syndrome has been treated with physostigmine for severe delirium or tachycardia. Benzodiazepines may be administered to decrease the likelihood of psychosis, agitation, and seizures in patients who are prone to these symptoms.
- Route of Exposure: Oral; topical ; parenteral(intramuscular or intravenous injection). Quickly absorbed with maximum activity occurring in approximately one hour.
- Carcinogenicity: No indication of carcinogenicity to humans (not listed by IARC).
- Toxicity: LD50: 500 mg/kg (Oral, Rat) (A308)
Mechanism of Action
|Target Name||Mechanism of Action||References|
Potassium voltage-gated channel subfamily H member 2
Muscarinic acetylcholine receptor M1
Muscarinic acetylcholine receptor M2
Muscarinic acetylcholine receptor M3
Muscarinic acetylcholine receptor M4
Histamine H4 receptor
Histamine H3 receptor
|Histamine H1 receptor||Diphenhydramine competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding.||
Diphenhydramine Interacts with Diseases
|Disease||Inference Score||References/Inference Genes|
|Cell Transformation, Neoplastic||6.56||
|Short QT Syndrome 1||5.54||
|Metabolic Syndrome X||5.34||
|Systemic carnitine deficiency||5.3||
|Long Qt Syndrome 2||4.85||